The involvement of skilled bioethicists is necessary for the success of research in the basic and translational sciences. In particular, research that is conducted to reduce the burdens caused by the racial disparities in cancer incidence requires bioethical guidance. For these reasons, the Bioethics Shared Resource (BESR) is an integral component of this Partnership. For full/pilot projects, the BESR provides consultation and collaborative support regarding ethical issues from design to implementation and assists in the development of grant proposals, abstracts, and manuscripts. In addition to its work supporting the research of Partnership investigators, the BESR enhances the bioethical capabilities of the Partnership participants. This is accomplished by providing education in bioethics to investigators, junior faculty, post-doctoral fellows, medical residents, graduate/undergraduate and medical students, community health advisors, navigators, partners, and other Partnership personnel regarding sound applications of bioethical principles in cancer research. The BESR provides bioethical education through the Research Education Core of the Partnership and, at TU, collaborates in teaching the graduate/undergraduate courses in bioethics in research, health disparities, and health policy. Bioethics support is essential for enhancing of the basic and translational research of the MSM/TU/UAB CCC Partnership.

Public Health Relevance

The Bioethics Shared Resource (BESR), coordinated through the Tuskegee University (TU) National Center for Bioethics in Health Care Research, will provide bioethics education, training, guidance, and consultation throughout the Morehouse School of Medicine/TU/the University of Alabama at Birmingham Comprehensive Cancer Center Partnership. Achieving appropriate bioethical competencies and integration ensures that research projects, outreach, and partnering with underserved and racial/ethnic minorities follow ethical guidelines.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
2U54CA118948-11
Application #
9211120
Study Section
Special Emphasis Panel (ZCA1-SRB-X (A1))
Project Start
Project End
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
11
Fiscal Year
2016
Total Cost
$9,436
Indirect Cost
$3,017
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Luo, Yanzhuo; Li, Bingjin; Zhang, Guangxin et al. (2018) Integrated Oncogenomic Profiling of Copy Numbers and Gene Expression in Lung Adenocarcinomas without EGFR Mutations or ALK Fusion. J Cancer 9:1096-1105
Wang, Chiung-Min; Yang, William H; Liu, Runhua et al. (2018) FOXP3 Activates SUMO-Conjugating UBC9 Gene in MCF7 Breast Cancer Cells. Int J Mol Sci 19:
Moore, Justin Xavier; Royston, Kendra J; Langston, Marvin E et al. (2018) Mapping hot spots of breast cancer mortality in the United States: place matters for Blacks and Hispanics. Cancer Causes Control :
Akinyemiju, Tomi; Moore, Justin Xavier; Pisu, Maria et al. (2018) A Prospective Study of Obesity, Metabolic Health, and Cancer Mortality. Obesity (Silver Spring) 26:193-201
Akinyemiju, Tomi; Moore, Justin Xavier; Judd, Suzanne E et al. (2018) Pre-diagnostic biomarkers of metabolic dysregulation and cancer mortality. Oncotarget 9:16099-16109
Piyathilake, Chandrika J; Badiga, Suguna; Borak, Samuel G et al. (2017) A higher degree of expression of DNA methyl transferase 1 in cervical cancer is associated with poor survival outcome. Int J Womens Health 9:413-420
Williams, Samuel K; Braxton, Joanne M; Gosdin, Melissa et al. (2017) Evidence-Based Care for the Elderly: Uses of ""the Grandmother Principle"". J Health Care Poor Underserved 28:7
Gao, Song; Wang, Yicun; Wang, Meng et al. (2017) MicroRNA-155, induced by FOXP3 through transcriptional repression of BRCA1, is associated with tumor initiation in human breast cancer. Oncotarget 8:41451-41464
Jia, Xu; Shanmugam, Chandrakumar; Paluri, Ravi K et al. (2017) Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer. Oncotarget 8:20198-20212
Zhang, Yifan; Li, Bingjin; Zhang, Xingyi et al. (2017) CD24 is a genetic modifier for risk and progression of prostate cancer. Mol Carcinog 56:641-650

Showing the most recent 10 out of 193 publications